Acetylcholine, histamine and cognition: two sides of the same coin by Blandina, Patrizio et al.
 10.1101/lm.68004Access the most recent version at doi:
 2004 11: 1-8Learn. Mem.
 
Patrizio Blandina, Marcel Efoudebe, Gabriele Cenni, et al.
 
Coin





Article cited in: 
 
 http://learnmem.cshlp.org/content/11/1/1.full.html#ref-list-1
This article cites 113 articles, 33 of which can be accessed free at:
service
Email alerting
 click heretop right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box at the
 http://learnmem.cshlp.org/subscriptions
 go to: Learning & MemoryTo subscribe to 
Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on October 6, 2012 - Published by learnmem.cshlp.orgDownloaded from 
Review
Acetylcholine, Histamine, and Cognition: Two Sides
of the Same Coin
Patrizio Blandina,1 Marcel Efoudebe, Gabriele Cenni, Pierfrancesco Mannaioni,
and Maria Beatrice Passani
Dipartimento di Farmacologia Preclinica e Clinica, V.le G. Pieraccini 6, Universita´ di Firenze, 50139 Firenze, Italy
The forebrain cholinergic neurons are localized in the nucleus
basalis magnocellularis (NBM), the major source of cholinergic
innervation to the neocortex and to the amygdala, and in the
medium septum-banda diagonalis complex, which provides cho-
linergic inputs to the hippocampus (Mesulam et al. 1983; Woolf
et al. 1984; Nicoll 1985). Basic and clinical studies have linked
dysfunctions of these neurons to cognitive decline (Everitt and
Robbins 1997; Givens and Sarter 1997). Their extensive loss is
characteristic of the forebrain of Alzheimer’s disease patients
(Davies and Maloney 1976; Coyle et al. 1983; Kuhl et al. 1999),
and anticholinergic drugs, such as scopolamine and atropine,
produce learning and memory deficits in a variety of cognitive
animal models (Deutsch 1971; Bartus and Johnson 1976; Enna-
ceur and Meliani 1992), and affect recognition memory in hu-
mans (Sperling et al. 2002; Sherman et al. 2003). Moreover, aged
rodents display both cognitive impairments in many learning
tasks (Ingram et al. 1994) and cholinergic deficits (Kubanis and
Zornetzer 1981; Decker 1987; Gallagher and Colombo 1995).
However, neuronal alterations associated with cognitive deficits
are not restricted to the cholinergic systems. For instance, dys-
functions of dopamine, GABA, noradrenaline, serotonin, and
histamine neurons have been identified in Alzheimer’s disease
(Hardy et al. 1985; Airaksinen et al. 1991; Panula et al. 1997;
Schneider et al. 1997), and region-selective decreases in dopa-
minergic, noradrenergic, or serotonergic contents are associated
with the level of age-related learning and memory impairments
(Stemmelin et al. 2000; Birthelmer et al. 2003). Abnormal inter-
actions between malfunctioning cholinergic and other neuro-
transmitter systems may cause additive or even synergistic effects
on cognition, a phenomenon that warrants the increasing inter-
est in understanding the complex physiology of brain systems
affecting cognitive processes. In this regard, the role of histamine
is gaining increasing attention (Passani et al. 2000; Passani and
Blandina 2003), and many recent results indicate that the hista-
minergic system influences learning and memory by modulating
the release of ACh (Passani et al. 2000; Bacciottini et al. 2001),
although some cognitive effects of histamine and histaminergic
agents occur independently of ACh. For example, local adminis-
tration of histamine failed to affect ACh release from the hippo-
campus (Bacciottini et al. 2002), yet improved fear memory by
H2- or H3-receptor-elicited erk2 activation in hippocampal CA3
cells (Giovannini et al. 2003). Nevertheless, histaminergic effer-
ents influence both the NBM-cortical (Clapham and Kilpatrick
1992; Blandina et al. 1996; Cecchi et al. 2001) and the medium
septum-banda diagonalis-hippocampal cholinergic pathways
(Mochizuki et al. 1994; Bacciottini et al. 2002; Fig. 1). The regu-
lation of ACh tone in different brain areas by neuronal histamine
also encompasses functions other than cognition. Histamine
promotes wakefulness by tonic control over sleep-generating
mechanisms in the preoptic/anterior hypothalamus, and cholin-
ergic neurons seem to be implicated (Lin et al. 1994; Brown et al.
2001). The aim of this review is to summarize some of the most
recent work on the interactions between histaminergic and cho-
linergic systems, and evaluate their role in cognitive and other
brain functions.
Histamine in the Central Nervous System
Histaminergic cell bodies are located exclusively in the tubero-
mammillary nucleus of the hypothalamus (Watanabe et al.
1983; Panula et al. 1984), which is also the sole location of his-
tidine decarboxylase immunoreactivity (Ericson et al. 1987), an
essential determinant of brain histamine levels (Kollonitsch et al.
1978; Green et al. 1987). These neurons project efferent varicose
fibers to all areas of the central nervous system (Inagaki et al.
1990). Histaminergic fibers are mostly unmyelinated and make
relatively few synaptic contacts, mainly with dendritic shafts
(Tohyama et al. 1991), with the exception of the mesencephalic
trigeminal nucleus, in which numerous synaptic contacts have
been observed by electron microscopy (Inagaki et al. 1987). His-
tamine interacts with specific receptors; three metabotropic, his-
taminergic receptor subtypes, H1, H2, and H3 have been de-
scribed in the mammalian central nervous system (Hill et al.
1997). Expression of a fourth histaminergic receptor was shown
in the peripheral tissue (Oda et al. 2000), but its presence in the
brain is still controversial (Liu et al. 2001a,b; Zhu et al. 2001). All
histaminergic receptors show a high degree of agonist-indepen-
dent activity. This phenomenon is referred to as constitutive ac-
tivity, and occurs in human, rat, and mouse recombinant recep-
tors expressed at physiological concentrations (Smit et al. 1996;
Bakker et al. 2000; Morisset et al. 2000; Wieland et al. 2001). It
has been suggested that constitutive activity of native H3 recep-
tors is one of the highest among G-protein-coupled receptors in
the brain (Rouleau et al. 2002). Constitutively active H3 receptors
presumably regulate histaminergic neurons, hence, the release of
histamine (Morisset et al. 2000). In this respect, the reclassifica-
tion of those H3 receptor antagonists such as clobenpropit, thio-
peramide, and ciproxifan that block constitutive activity, as in-
verse agonists, may have therapeutic relevance. Either inverse
agonists or neutral antagonists may be favorable for different
clinical applications. Some histaminergic neurons also store neu-
roactive substances and related enzymes, such as GABA (Ericson
1991), glutamate decarboxylase (Takeda et al. 1984), adenosine
deaminase (Senba et al. 1985), substance P (Köhler et al. 1985)
and galanin (Köhler et al. 1986), in a species-specific manner
(Airaksinen 1992), but the functional significance of these colo-
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calizations is unknown at the moment. The morphological fea-
tures of the central histaminergic system, with a compact cell
group and a widespread distribution of varicose fibers, resembles
that of other biogenic amines, such as norepinephrine and sero-
tonin, thus suggesting that the histaminergic systemmay also act
as a regulatory center for whole-brain activity (Wada et al. 1991).
Histaminergic neurons fire spontaneously (Reiner 1987; Haas
and Reiner 1988) at a low rate during sleep and a high rate during
waking and attention (Sakai et al. 1990). The interactions with
orexin neurons (Eriksson et al. 2001; Huang et al. 2001) further
indicate that histamine is required for arousal. Orexin is a pep-
tidergic neurotransmitter affecting feeding and wakefulness, and
its deficit has a crucial role in narcolepsy (Chemelli et al. 1999).
Several investigations support the idea that the level of arousal
affects retention and consolidation of memories (Cahill and Mc-
Gaugh 1995), thus, neuronal histamine may affect cognitive pro-
cesses by modulating neuronal functions throughout the brain,
according to the animal state. Nevertheless, recent findings in-
dicate that the histaminergic system may also directly influence
neurobiological processes underlying learning and memory
(Passani et al. 2000; Passani and Blandina 2003).
Histamine Modulates ACh Release From the Amygdala
and Emotional Memory in a Bimodal Fashion
Emotional memory may be assessed with adversely motivated
training tasks, such as contextual fear conditioning. In this test,
the experimental animal learns to associate a mild electrical foot-
shock with the environment in which it receives the punish-
ment. Re-exposure to the same environment will induce, even in
the absence of the punishment, a stereotyped behavior, denomi-
nated freezing that is characterized by the complete absence of
voluntary movements. The time spent freezing during recall is
correlated with animal memory ability, as an amnesic animal will
spend less time freezing during recall, than a normal one. There
is extensive evidence that crucial neural changes mediating emo-
tional memory occur in the basolateral amygdala (BLA; Davis
1992; LeDoux 2000). For instance, fear memory retention is im-
paired by posttraining inactivation of this area by lidocaine
(Dalmaz et al. 1993) or tetrodotoxin (Sacchetti et al. 1999), and
the pharmacological manipulation of the BLA with drugs influ-
encing the cholinergic system affects memory consolidation for
adverse events (Introini-Collison et al. 1996; Vazdarjanova and
McGaugh 1999). The injection of H3 receptor antagonists/inverse
agonists into the BLA decreases the freezing time of trained rats
compared with saline-injected controls (Passani et al. 2001), thus
causing an amnesic effect (Fig. 2A). Conversely, intra-BLA injec-
tion of H3 receptor agonists augments the freezing time (Cangioli
et al. 2002), which is an indication of procognitive effects (Fig.
2A). In these experiments, the drugs were injected immediately
after training, and the retention test was carried out after 3 d,
thus avoiding any influence on acquisition and/or other pro-
cesses that indirectly may affect learning (McGaugh and Izqui-
erdo 2000). Hence, H3-ligands directly modulate fear-memory
consolidation processes. Because several studies have shown that
manipulation of cholinergic neurotransmission within the BLA
affects the expression of memory after fear conditioning (Mc-
Gaugh 2000), the effects of H3 ligands on amygdalar ACh release
were addressed using the microdialysis technique that allows the
collection of extracellular fluid, and the delivery of drugs to very
discrete brain areas. Local perfusion with either H3-antagonists/
inverse agonists or H3-agonists, at concentrations comparable
with those that affected fear memory in the behavioral experi-
ments, decrease (Passani et al. 2001) or increase (Cangioli et al.
2002) ACh release from the BLA, respectively (Fig. 2B). Consis-
tent with previous findings (Introini-Collison et al. 1996; Vazdar-
janova and McGaugh 1999), these observations stress the impor-
tance of BLA cholinergic tone for consolidation of fear memories.
Furthermore, they demonstrate that histaminergic compounds
modify the expression of fear memories in a bimodal fashion,
and modulate the cholinergic tone within the amygdala accord-
ingly. The BLA receives abundant cholinergic innervation from
the nucleus basalis magnocellularis (Mesulam et al. 1983; Carlsen
et al. 1985), and displays high H3-receptor binding (Pollard et al.
1993) and expression of its gene transcripts (Lovenberg et al.
1999). H3 receptors act as inhibitory auto- and hetero-receptors,
thus inhibiting histamine synthesis and release as well as the
release of other neurotransmitters, including ACh (Blandina et al.
1998; Haas and Panula 2003). In the BLA, H3 receptor binding
is strictly associated with the presence of histaminergic fibers
(Anichtchik et al. 2000), and local perfusion with H3 receptor
antagonists/inverse agonists increases endogenous histamine re-
lease (Cenni et al. 2003); therefore, the inhibition of ACh release
Figure 1 Schematic representation of the interactions between the
cholinergic and histaminergic systems in some regions of the rat brain.
The location of histaminergic receptors is inferred from results obtained
using the microdialysis technique (see text). (BLA) basolateral amygdala;
(Cx) cortex; (NBM) nucleus basalis magnocellularis; (TM) tuberomammi-
lary nucleus.
Blandina et al.
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elicited by H3-antagonists/inverse agonists could be most simply
explained by a blockade of inhibitory H3 autoreceptors (Fig. 1).
Blockade of H3 autoreceptors augments histamine release in the
BLA, which, in turn, moderates cholinergic neurotransmission,
presumably by activation of postsynaptic H2 receptors, as pre-
treatment with cimetidine fully antagonizes cholinergic inhibi-
tion caused by H3 antagonists/inverse agonists (Passani et al.
2001). The opposite may occur when H3 receptors are activated.
These results are in agreement with the impairing effect of his-
tamine administered into the BLA on the acquisition of an avoid-
ance task (Alvarez and Ruarte 2002). In this learning paradigm,
animals are trained in a two-compartment cage with a wall sepa-
rating the compartments. Animals are conditioned to escape
from the punishment box, where they receive a mild foot-shock,
to the safe box. The punishment is preceded by an ultrasonic
tone, which subsequently will elicit the escape, even without the
foot-shock. The latency of escape is an indication of how well the
animal remembers. Histamine administered locally to the BLA,
increases the escape latency and impairs learning.
The evidence reviewed above renders the histaminergic sys-
tem one of the conceivable neural bases mediating hypothalamic
influences on the storage of emotionally based memories. Fur-
thermore, it may provide the fine-tuning of ACh release neces-
sary to produce the adequate behavioral response.
Histamine Influence on Memory Depends on the Brain
Region and the Cognitive Task Involved
Although H3 antagonists/inverse agonists impair contextual fear
conditioning (Passani et al. 2001), their administration produces
significant enhancement in several cognitive tasks. Pharmaco-
logical blockade of H3 receptors in the adult rat significantly im-
proves social memory (Prast et al. 1996), enhances attention as
evaluated in the five-choice, serial-reaction time test (Ligneau et
al. 1998), and improves cognitive performance in the five-trial
inhibitory avoidance task (Fox et al. 2002, 2003). Procognitive
effects of H3 receptor antagonists/inverse agonists have been ob-
served also in cognitively impaired animals. For example, thiop-
eramide significantly improves the response latency in a passive
avoidance response in senescence-accelerated mice, character-
ized by a marked age-accelerated deterioration in learning tasks
(Meguro et al. 1995). Consistently, two H3 receptor antagonists/
inverse agonists, thioperamide, and clobenpropit, fully reverted
scopolamine-elicited impairments in a passive avoidance re-
sponse and object-recognition test in the rat (Giovannini et al.
1999). Similarly, FUB 181, an H3 receptor antagonist (Stark et al.
1998), significantly ameliorates performances of scopolamine-
impaired mice in the elevated plus-maze test (Onodera et al.
1998). Cognitive performance is also improved in spontaneously
hypertensive rat (SHR) pups challenged in a five-trial avoidance
test, following administration of A-304121 or A-317920. These
are non-imidazole compounds of particular interest for clinical
application, because of a lower potential for metabolic interac-
tions and receptor-binding promiscuity than most known an-
tagonists/inverse agonists of the H3 receptor (Hough 2001; Es-
benshade et al. 2003). Juvenile SHR rats are normotensive, but
exhibit many cognitive impairments (Fox et al. 2002, 2003). Be-
cause these deficits are genetic in origin, this model appears more
clinically relevant than those requiring additional pharmacologi-
cal or surgical intervention.
In rats, as in humans, projections from the NBM provide the
majority of cholinergic innervation to the cortex (Mesulam et al.
1983; Heckers et al. 1994). Both in vitro (Clapham and Kilpatrick
1992; Arrang et al. 1995), and in vivo (Blandina et al. 1996)
experiments demonstrated that locally applied histamine de-
creases the cholinergic tone in the cortex through activation of
H3 receptors. This interaction may have functional relevance, as
systemic administration of H3 receptor agonists impairs rat per-
Figure 2 (A) Effects of posttraining bilateral injections of an H3 receptor
antagonist (thioperamide) or an H3 receptor agonist (R--methylhista-
mine/RAMH) into BLA on contextual fear conditioning. Rats were injected
immediately after training under general anesthesia (ketamine, 100 mg/
kg i.p.). Each drug was freshly prepared and diluted in sterile saline to
permit the injection of a constant volume of 0.5 µL/side to each rat.
Solutions were injected over a 1–2 min period, and the needle was left in
place for another minute before withdrawal. Controls were injected with
saline. At 72 h after training, freezing was measured during the first 3-min
period of the retesting. Each bar represents the mean value SEM of (n)
experiments. **P < 0.01 vs. control (ANOVA and Neuman-Keuls’ test). (B)
Effect of thioperamide and RAMH on ACh spontaneous release from the
BLA of freely moving rats. ACh was measured in fractions collected every
20 min, beginning 2 h after the onset of the perfusion. Spontaneous
release of ACh was calculated for each experiment by averaging the mean
of the four initially collected 20-min samples of perfusate, and ACh re-
lease was expressed as percentage of its spontaneous release value. Mean
value of ACh spontaneous release averaged 0.12 0.02 pmole/20 min
in the experiments with RAMH (n = 5), and 0.26 0.05 pmole/20 min
in those with thioperamide (n = 4). The bar indicates the period of thio-
peramide application. Thioperamide (300 nM) or RAMH (10 µM) were
administered into the BLA through the dialysis probe; the bar indicates
the period of drug application. Shown are means  SEM of four experi-
ments (thioperamide) and five experiments (RAMH). (Passani et al. 2001;
Cangioli et al. 2002, modified).
Cholinergic and Histaminergic Interactions
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formance in object recognition, and in a passive avoidance re-
sponse at the same doses that reduced ACh release from freely
moving rat cortex (Blandina et al. 1996). This was the first evi-
dence that related the cognitive effects of histamine to modifi-
cations of ACh neurotransmission, and agrees with the observa-
tions that reduced availability of ACh in the synaptic cleft results
in cognitive deficits (Quirion et al. 1995). H3 receptor-induced
inhibition of cortical ACh is abolished in cortices in which the
traffic of action potentials was blocked by tetrodotoxin (Blandina
et al. 1996), thus strongly suggesting that H3 receptors modulat-
ing cortical ACh release are located postsynaptically on intrinsic
perikarya (Arrang et al. 1995). Microdialysis experiments demon-
strated that immepip, an H3 receptor agonist, increases GABA
release from the cortex of freely moving rats, and bicuculline, a
GABAA receptor antagonist, reverses the inhibition of ACh re-
lease induced by immepip (Giorgetti et al. 1997). Thus, it is con-
ceivable that H3 heteroreceptors facilitate GABA release, which,
in turn, inhibit ACh release. Cortical GABAergic interneurons
control the activity of large populations of principal cells
through their extensive axon arborization (Freund and
Meskenaite 1992). Therefore, any pathway, even if relatively
sparse, such as the histaminergic pathway, may exert a powerful
effect on the activity of the cortex if it modulates the activity of
local GABAergic interneurons. The observation that H3 receptor
agonists moderated ACh release and impair cognition (Blandina
et al. 1996), by inference, may account for the procognitive ef-
fects of H3 receptor antagonists reviewed above. Yet, in this re-
gard, another observation may be relevant. Histaminergic modu-
lation of cortical cholinergic tone appears to be complex, and
consists of two components, one inhibitory, related to local ac-
tions at the terminals, the other excitatory, resulting from inter-
actions with cholinergic cell bodies in the NBM (Fig. 1). The
administration of H3 antagonists/inverse agonists, such as clo-
benpropit or thioperamide into the NBM, increased the output of
ACh from the cortex of rats implanted with two microdyalisis
probes, one in the NBM to locally deliver the different drugs, and
the other in the cortex to measure the output of ACh (Cecchi et
al. 2001). H3 autoreceptors appear to be involved, because perfu-
sion of rat NBM with the same compounds elicit a local increase
of endogenous histamine (P. Blandina, unpubl.). Pretreatment
with triprolidine fully blocks the effect of thioperamide on cor-
tical ACh release (Cecchi et al. 2001), thus implicating postsyn-
aptic H1 receptors. This finding is consistent with a report that
histamine depolarizes the membrane and increases the tonic fir-
ing of guinea-pig nucleus basalis magnocellularis cholinergic
neurons through H1 receptor activation (Khateb et al. 1995). Fur-
ther, rats that received i.c.v. administrations of the selective H1
receptor agonist 2-(3-(trifluoromethyl)-phenyl)histamine per-
formed better than saline-injected animals in the object-
recognition task (Malmberg-Aiello et al. 2003). On the other
hand, the performance in attention-demanding tasks deterio-
rates after treatment with H1 receptor antagonist at doses that fail
to cause changes in subjective sleepiness (Okamura et al. 2000).
The evidence reviewed above supports the hypothesis that acti-
vation of the dense histaminergic innervation to the NBM facili-
tates the cholinergic tone in the cortex. Working memory tasks,
as well as noncognitive stimuli, such as stress or sensory stimu-
lation (Pepeu and Blandina 1998), activate the cortical circuitry
that requires ascending excitatory influx from the brainstem, in-
volving several neurotransmitters such as ACh, GABA, gluta-
mate, histamine, and noradrenaline (Nicoll et al. 1990; McCor-
mick andWilliamson 1991). The NBM cholinergic system, which
plays an important role in cortical activation (Steriade and
Buzsaki 1990), may therefore represent the final pathway of sev-
eral inputs (Pepeu and Blandina 1998). These interactions may
have implications for cognitive decline associated with aging and
Alzheimer’s disease. The different degrees of degeneration of vari-
ous transmitter systems and their possible mutual compensatory
effects may account for individual differences in cognitive capa-
bilities. In fact, aging is not necessarily associated with alter-
ations of learning and memory abilities (Rapp and Amaral 1992),
and different levels of impairment are observed in Alzheimer’s
disease. Interestingly, binding of H1 receptors, assessed by posi-
tron emission tomography, is significantly decreased in the brain
of Alzheimer’s disease patients compared with those of normal
subjects (Higuchi et al. 2000), thus revealing a disruption of the
histaminergic neurotransmission in this pathology. The charac-
teristic cortical cholinergic dysfunction may result from cell de-
generation of both cholinergic and noncholinergic neurons of
the NBM (Whitehouse et al. 1982), and from reduction in im-
pulse flow from the NBM to the cortex (Aston-Jones et al. 1985).
Loss of cholinergic neurons would reduce the cortical cholinergic
activity directly, yet degeneration of noncholinergic neurons
may contribute to cholinergic hypofunction. These observations
can be readily integrated; loss of NBMGABA neurons (Gritti et al.
1997), which project primarily to cortical GABA interneurons
(Freund and Meskenaite 1992), would increase the cortical
GABAergic inhibitory tone on ACh release (Giorgetti et al. 2000).
Also, the decrease of excitatory inputs to the NBM cholinergic
neurons, because of the reduction of H1 receptors, may contrib-
ute to the cortical cholinergic hypofunction.
Not Only Cognition: Interactions Between
Histaminergic and Cholinergic Neurons Affect Arousal
Diminished alertness, slowed reaction times, and somnolence are
common manifestations of treatments with H1 antagonists, thus
suggesting that histamine is required for arousal. The evidence
became persuasive with the report that histidine decarboxylase
knockout mice, which lack histamine, display increased para-
doxical sleep, cortical-EEG changes, sleep-wake cycle modifica-
tions, and are unable to remain awake when high vigilance is
required, such as at light-off or during environmental changes
(Parmentier et al. 2002). Furthermore, orexin seems to have an
important role in sleep regulation (Mignot et al. 2002), and the
arousal effects of the orexin system depends on the activation of
the histaminergic neurons (Huang et al. 2001). The interplay
between the two systems was also demonstrated in orexin recep-
tor-2 mutated, narcoleptic dogs; these animals have significantly
lower levels of histamine in the cortex and thalamus, whereas
other neurotransmitter systems are unaffected (Nishino et al.
2001). Cortical activation (EEG desynchronization) is one of the
salient signs of wakefulness and requires high cholinergic, hista-
minergic, noradrenergic, and serotonergic tones (Mignot et al.
2002). Histaminergic neurons activate the cortex directly via
their widespread hypothalamo-cortical projections or, indirectly,
by stimulating the serotonergic raphe neurons (Brown et al.
2002). In addition, they activate the cholinergic corticopetal sys-
tem originating from the nucleus basalis magnocellularis (Cecchi
et al. 2001) and the substantia innominata (Lin et al. 1994). Also,
cholinergic projections to the thalamus and the hypothalamus
are critical to cortical activation, complementing the direct cho-
linergic projections from the basal forebrain to the cortex. His-
taminergic-descending afferents excite cholinergic neurons in
the mesopontine tegmentum, which, in turn, projects to the
thalamus and the hypothalamus, thus eliciting cortical activa-
tion through thalamo- and hypothalamo-cortical circuitries (Lin
et al. 1996). The excitatory interactions between histaminergic
and cholinergic neurons in the basal forebrain, the hypothala-
mus, and the mesopontine tegmentum constitute a crucial
mechanism within the ascending neuronal network responsible
for the maintenance of cortical activation and wakefulness.
Blandina et al.
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Concluding Remarks
A wide variety of studies agree that the neuronal histaminergic
system interacts with cholinergic neurons to regulate arousal and
some forms of cognition.
Our understanding of both physiological and pathological
mechanisms of sleep and cognitive disorders requires learning
the neural basis of these functions. In addition to histaminergic
and cholinergic neurons, other neurotransmitter systems are cer-
tainly implicated, although it is not known to what extent. This
is particularly true for arousal, in which the hypothalamus plays
a key role; hypothalamic neurotransmitter systems (adenosine,
dopamine, GABA, histamine, and orexin) along with extra-
hypothalamic cholinergic systems provide the framework for
most models of sleep regulation (Mignot et al. 2002). The infor-
mation obtained from these studies may have therapeutic appli-
cations for treating sleep disorders. Concerning cognition, inter-
actions between the histaminergic and cholinergic systems serve
as one of the physiological correlates of the ability of animals to
learn and remember (Passani et al. 2000; Bacciottini et al. 2001;
Passani and Blandina 2003). Treatment strategies of cognitive
impairments have traditionally been aimed at restoring the cho-
linergic neurotransmission, yet therapies with cholinesterase in-
hibitors or muscarinic agonists have been generally unproduc-
tive, as the improvements of cognitive functions are generally
modest and confined to a minority of patients (Kelly 1999). One
explanation could be that cholinergic drugs used in most clinical
trials produce a greater stimulation of inhibitory autoreceptors,
either by increasing the half-life of ACh in the synaptic cleft
(Davis et al. 1992), or by directly activating these receptors
(Gauthier et al. 1991). Histamine receptors could represent the
target for compounds, which, taking advantage of noncholiner-
gic mechanisms potentiate cholinergic functions, and may pro-
duce beneficial effects on disorders in which the cholinergic
function is compromised. Yet, ACh/histamine interactions are
complex and multifaceted, and the results are often contradic-
tory, as both facilitatory and inhibitory effects of histamine on
memory have been described (Blandina et al. 1996; Passani et al.
2001; Cangioli et al. 2002). The precise timing of histamine re-
lease, the distinct actions that the histaminergic system might
exert by activating different receptor subtypes, the architectural
constraints that separate groups of transmitters in particular
brain structures, and the nature of the cognitive task used may
determine whether histamine has facilitatory or inhibitory ef-
fects. As it turned out, histaminergic H3 receptor activation, for
instance, modulates ACh release and cognitive processes, appar-
ently with modalities that differ according to their role as auto-
or heteroreceptors (Blandina et al. 1996; Cecchi et al., 2001;
Passani et al. 2001; Cangioli et al. 2002). Thus, it will be necessary
to develop drugs not only selective for the receptor subtypes, but
also specific for the particular brain region of interest. Multiple
mRNA isoforms for the H3 receptor have been described in rats,
guinea pigs, and humans (Tardivel-Lacombe et al. 2000; Coge et
al. 2001; Drutel et al. 2001; Wellendorph et al. 2002). Functional
receptor isoforms of the H3 receptor display different pharmaco-
logical profiles (Wellendorph et al. 2002), and are distributed in
the CNS in a heterogeneous fashion (Drutel et al. 2001). Thus,
there is increasing interest, and great effort is being channeled
into developing ever-more selective agonists, inverse agonists,
pure antagonists for the H3 receptor, as well as ligands for its
various isoforms. This will be a great challenge for the molecular
pharmacology in the years to come. Obviously, new discoveries
create tremendous expectations, as these compounds have po-
tential ameliorating effects in disorders such as Attention Deficit/
Hyperactivity Disorder, Alzheimer’s Disease, Mild Cognitive Im-
pairment, and anorexia as proposed elsewhere (Leurs et al. 1998;
Passani and Blandina 2003).
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